Aquapharm Biodiscovery, a Scottish biotech aiming to discover new antibiotics and antioxidants from marine organisms, raised $8.3 million (£4 million) in a second funding round (PDF). The company, based near Oban in the European Center for Marine Biotechnology, harvests and …
Alacrity Biosciences, a Laguna Hills, Calif., biotech developing eye treatments, raised $4.9 million in bridge financing while it gathers clinical data in support of a larger first round later this year, VentureWire reports (subscription required). The funding was provided by …
Israel’s NeuroDerm (the page is currently a placeholder), a biotech developing drug patches for neurological disorders such as Parkinson’s disease, raised $2.5 million in a first round of funding. The investment was provided by private individuals, including Robert Taub, founder …
KaloBios, a Palo Alto, Calif., biotech antibody-therapeutic company, raised $20 million in a third funding round. The company is developing new drugs based on monoclonal antibodies, which target specific cells or proteins in the body. Its lead candidate, an antibody …
Palo Alto, Calif.-based Horizon Therapeutics, a biotech that aims to combine existing generic drugs to fight pain, raised $30 million in a third funding round. The company’s lead drug candidate, known only as HZT-501, is a “proprietary” combination of the …
Venture-capital financing may be at a six-year high, but the picture in life sciences is a mixed one. After a blowout first quarter, second-quarter fundings in biotechnology actually dropped 19 percent, to $1.1 billion, compared to the same period last …
Zurich’s GlycoVaxyn, a biotech developing new “conjugated vaccines”, raised a $9.3 million first funding round. Sofinnova Partners and Index Ventures supplied the investment.
The company will use the funding to push forward with the development of vaccines for bacterial infections, …
At a first glance, San Francisco’s Nuon Therapeutics looks like any other specialty-pharmaceutical company that aims to pick up cast-off or failed drugs and try to squeeze some new life out of them. That sort of business model is frequently …
Novocell, a San Diego embryonic stem-cell company, raised $25 million in a third round of funding. That’s presumably a bit of a letdown for the company, which had previously hoped to pull in as much as $35 million in the …
ImaRx, a Tuscon, Ariz., biotech developing new ways to dissolve blood clots in the lungs, lowered its IPO sights and now expects to raise no more than $17.3 million in the offering. (Its latest SEC filing is here.) Late last …
Viroblock, a Geneva-based biotech focused on new antiviral drugs, raised a first round of funding. The company didn’t disclose financial details; its release is here. The round was led by private investor Peter Pfister, Fongit Seed Invest, and Initiative Capital …
Diamics, a Novato, Calif., maker of cancer diagnostics, raised $6 million by selling a 51 percent stake to Inverness Medical Innovations, a publicly traded diagnostic company.
Diamics is developing an improved system for taking Pap smears used in the early …
Adimab, a Lebanon, N.H., biotech startup developing a “platform” for the discovery and commercialization of yeast-derived antibodies, raised $6 million in a first funding round (hat tips to the In Vivo Blog and VentureWire). The company was founded by Darthmouth’s …
Santa Monica, Calif.-based Agensys, a biotech focused on new cancer drugs, raised $41 million in a fourth funding round. Duquesne Capital Management and JAFCO led the round, joined by Innovis Investments, Nextech Venture, Bear Stearns Health Innoventures, Alta Partners, HBM …
(UPDATED: See below.)
Sunrise, Fla.-based Bioheart thinks enough of its stem-cell treatment for heart disease that it has just boosted its expected IPO take by $10 million, to $45 million. A close reading of its latest SEC filing, however, …
Snoqualmie, Wash.-based Light Sciences Oncology, a developer of light-activated cancer drugs, raised $30 million in a second funding round, even though it still has an IPO registration on file with the SEC. The latest funding closes out the company’s second …
Coda Genomics, a Laguna Hills, Calif., biotechnology company founded in 2005, concentrates on a thorny but little-realized challenge in biotechnology: Genetic engineering is easy. Protein manufacture is hard.
The biotech industry was founded on the science of recombinant DNA, which …
Protiva, a Vancouver, B.C.-based developer of drugs based on the new technology of RNA interference, raised $3.3 million in debenture financing. Investors included GrowthWorks Capital, BDC Capital, the Canadian Medical Discoveries Fund and Kinetic Capital.
Protiva is currently embroiled in …
Cary, N.C.-based NephroGenex, a biotech developing personalized therapies for kidney disease, raised $3.3 million of an expected $26.8 million first funding round, VentureWire reports (subscription required), citing an SEC filing (no link available). There’s another report that cites PE Wire …
NanoBioDesign, a London developer of systems that screen experimental drugs against key liver enzymes, raised $1 million (£500,000) to support manufacturing of its protein-chip devices. The funding was provided by the Imperial Innovations Group and the Capital Fund.
NanoBioDesign is …
